Univariate analyses of a 7-SNP–based classifier and clinicopathological characteristics associated with PFS and OS
| Variables . | Training cohort . | Internal validation cohort . | External validation cohort 1 . | External validation cohort 2 . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| PFS | ||||||||
| Age (≤60 vs >60 y) | 1.456 (0.981-2.160) | .062 | 1.887 (0.997-3.646) | .059 | 1.892 (1.142-3.133) | .013 | 1.634 (0.959-2.784) | .071 |
| Sex (male vs female) | 0.825 (0.595-1.146) | .252 | 1.067 (0.618-1.834) | .817 | 1.058 (0.655-1.707) | .819 | 0.783 (0.422-1.453) | .438 |
| B symptoms (no vs yes) | 1.277 (0.945-1.726) | .112 | 1.659 (0.992-2.774) | .054 | 1.322 (0.842-2.077) | .226 | 2.203 (1.299-3.737) | .003 |
| ECOG-PS (0-1 vs ≥2) | 1.856 (1.175-2.933) | .008 | 1.570 (0.774-3.315) | .237 | 2.045 (1.017-4.114) | .045 | 2.319 (1.334-4.029) | .003 |
| Ann Arbor stage (I-II vs III-IV) | 2.496 (1.806-3.450) | <.001 | 2.155 (1.235-3.760) | .007 | 2.868 (1.809-4.548) | <.001 | 3.173 (1.860-5.412) | <.001 |
| Lymphoma node involvement (none or regional vs distant) | 1.697 (1.110-2.596) | .015 | 2.042 (1.082-3.855) | .028 | 1.850 (1.155-2.963) | .010 | 2.982 (1.637-5.432) | <.001 |
| Nonnasal type (no vs yes) | 1.660 (1.144-2.409) | .008 | 1.930 (1.094-3.430) | .023 | 2.288 (1.229-4.262) | .009 | 2.507 (1.255-5.008) | .009 |
| Extranodal involvement (0-1 vs ≥2 nodes) | 1.840 (1.361-2.486) | <.001 | 1.694 (0.972-2.953) | .063 | 1.875 (1.193-2.946) | .006 | 2.628 (1.556-4.439) | <.001 |
| LDH (normal vs elevated) | 1.839 (1.360-2.486) | <.001 | 1.940 (1.163-3.237) | .011 | 1.967 (1.253-3.090) | .003 | 1.624 (0.947-2.783) | .078 |
| 7-SNP–based classifier (low risk vs high risk) | 3.431 (2.479-4.750) | <.001 | 3.705 (2.104-6.526) | <.001 | 3.778 (2.313-6.171) | <.001 | 4.593 (2.554-8.259) | <.001 |
| OS | ||||||||
| Age (≤60 vs >60 y) | 1.536 (1.018-2.316) | .041 | 2.292 (1.172-4.483) | .015 | 2.066 (1.204-3.543) | .008 | 1.729 (0.974-3.068) | .061 |
| Sex (male vs female) | 0.857 (0.608-1.210) | .381 | 1.609 (0.598-1.910) | .822 | 1.066 (0.631-1.800) | .811 | 0.826 (0.431-1.583) | .565 |
| B symptoms (no vs yes) | 1.421 (1.034-1.953) | .030 | 1.352 (0.785-2.331) | .277 | 1.695 (1.034-2.783) | .036 | 2.175 (1.234-3.835) | .007 |
| ECOG-PS (0-1 vs ≥2) | 1.805 (1.115-2.921) | .016 | 1.575 (0.709-3.501) | .265 | 2.349 (1.156-4.773) | .018 | 2.725 (1.542-4.815) | .001 |
| Ann Arbor stage (I-II vs III-IV) | 2.512 (1.787-3.533) | <.001 | 2.162 (1.194-3.917) | <.001 | 3.260 (1.966-5.406) | <.001 | 3.178 (1.772-5.699) | <.001 |
| Lymphoma node involvement (none or regional vs distant) | 1.889 (1.229-2.904) | .004 | 1.893 (1.082-3.312) | .025 | 2.130 (1.276-3.554) | .004 | 2.715 (1.407-5.242) | .003 |
| Nonnasal type (no vs yes) | 1.858 (1.267-2.725) | .002 | 1.695 (0.914-3.141) | .094 | 1.978 (0.971-4.029) | .060 | 2.341 (1.126-4.856) | .023 |
| Extranodal involvement (0-1 vs ≥2 nodes) | 1.774 (1.289-2.441) | <.001 | 1.869 (1.043-3.349) | .035 | 2.400 (1.443-3.993) | .001 | 2.974 (1.662-5.323) | <.001 |
| LDH (normal vs elevated) | 1.859 (1.352-2.557) | <.001 | 2.007 (1.162-3.465) | .012 | 2.010 (1.219-3.315) | .006 | 1.891 (1.032-3.463) | .039 |
| 7-SNP–based classifier (low risk vs high risk) | 4.010 (2.808-5.727) | <.001 | 3.059 (1.691-5.536) | <.001 | 3.846 (2.228-6.640) | <.001 | 3.249 (1.773-5.954) | <.001 |
| Variables . | Training cohort . | Internal validation cohort . | External validation cohort 1 . | External validation cohort 2 . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| PFS | ||||||||
| Age (≤60 vs >60 y) | 1.456 (0.981-2.160) | .062 | 1.887 (0.997-3.646) | .059 | 1.892 (1.142-3.133) | .013 | 1.634 (0.959-2.784) | .071 |
| Sex (male vs female) | 0.825 (0.595-1.146) | .252 | 1.067 (0.618-1.834) | .817 | 1.058 (0.655-1.707) | .819 | 0.783 (0.422-1.453) | .438 |
| B symptoms (no vs yes) | 1.277 (0.945-1.726) | .112 | 1.659 (0.992-2.774) | .054 | 1.322 (0.842-2.077) | .226 | 2.203 (1.299-3.737) | .003 |
| ECOG-PS (0-1 vs ≥2) | 1.856 (1.175-2.933) | .008 | 1.570 (0.774-3.315) | .237 | 2.045 (1.017-4.114) | .045 | 2.319 (1.334-4.029) | .003 |
| Ann Arbor stage (I-II vs III-IV) | 2.496 (1.806-3.450) | <.001 | 2.155 (1.235-3.760) | .007 | 2.868 (1.809-4.548) | <.001 | 3.173 (1.860-5.412) | <.001 |
| Lymphoma node involvement (none or regional vs distant) | 1.697 (1.110-2.596) | .015 | 2.042 (1.082-3.855) | .028 | 1.850 (1.155-2.963) | .010 | 2.982 (1.637-5.432) | <.001 |
| Nonnasal type (no vs yes) | 1.660 (1.144-2.409) | .008 | 1.930 (1.094-3.430) | .023 | 2.288 (1.229-4.262) | .009 | 2.507 (1.255-5.008) | .009 |
| Extranodal involvement (0-1 vs ≥2 nodes) | 1.840 (1.361-2.486) | <.001 | 1.694 (0.972-2.953) | .063 | 1.875 (1.193-2.946) | .006 | 2.628 (1.556-4.439) | <.001 |
| LDH (normal vs elevated) | 1.839 (1.360-2.486) | <.001 | 1.940 (1.163-3.237) | .011 | 1.967 (1.253-3.090) | .003 | 1.624 (0.947-2.783) | .078 |
| 7-SNP–based classifier (low risk vs high risk) | 3.431 (2.479-4.750) | <.001 | 3.705 (2.104-6.526) | <.001 | 3.778 (2.313-6.171) | <.001 | 4.593 (2.554-8.259) | <.001 |
| OS | ||||||||
| Age (≤60 vs >60 y) | 1.536 (1.018-2.316) | .041 | 2.292 (1.172-4.483) | .015 | 2.066 (1.204-3.543) | .008 | 1.729 (0.974-3.068) | .061 |
| Sex (male vs female) | 0.857 (0.608-1.210) | .381 | 1.609 (0.598-1.910) | .822 | 1.066 (0.631-1.800) | .811 | 0.826 (0.431-1.583) | .565 |
| B symptoms (no vs yes) | 1.421 (1.034-1.953) | .030 | 1.352 (0.785-2.331) | .277 | 1.695 (1.034-2.783) | .036 | 2.175 (1.234-3.835) | .007 |
| ECOG-PS (0-1 vs ≥2) | 1.805 (1.115-2.921) | .016 | 1.575 (0.709-3.501) | .265 | 2.349 (1.156-4.773) | .018 | 2.725 (1.542-4.815) | .001 |
| Ann Arbor stage (I-II vs III-IV) | 2.512 (1.787-3.533) | <.001 | 2.162 (1.194-3.917) | <.001 | 3.260 (1.966-5.406) | <.001 | 3.178 (1.772-5.699) | <.001 |
| Lymphoma node involvement (none or regional vs distant) | 1.889 (1.229-2.904) | .004 | 1.893 (1.082-3.312) | .025 | 2.130 (1.276-3.554) | .004 | 2.715 (1.407-5.242) | .003 |
| Nonnasal type (no vs yes) | 1.858 (1.267-2.725) | .002 | 1.695 (0.914-3.141) | .094 | 1.978 (0.971-4.029) | .060 | 2.341 (1.126-4.856) | .023 |
| Extranodal involvement (0-1 vs ≥2 nodes) | 1.774 (1.289-2.441) | <.001 | 1.869 (1.043-3.349) | .035 | 2.400 (1.443-3.993) | .001 | 2.974 (1.662-5.323) | <.001 |
| LDH (normal vs elevated) | 1.859 (1.352-2.557) | <.001 | 2.007 (1.162-3.465) | .012 | 2.010 (1.219-3.315) | .006 | 1.891 (1.032-3.463) | .039 |
| 7-SNP–based classifier (low risk vs high risk) | 4.010 (2.808-5.727) | <.001 | 3.059 (1.691-5.536) | <.001 | 3.846 (2.228-6.640) | <.001 | 3.249 (1.773-5.954) | <.001 |